1. Home
  2. Live Updates
  3. Mm treatment

Live Breaking News & Updates on Mm treatment

Stay informed with the latest breaking news from Mm treatment on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Mm treatment and stay connected to the pulse of your community

Treatment Considerations and Sequencing in Multiple Myeloma

The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.

Multiple-myeloma , Mm , Relapsed-refractory-mm , Rrmm , Mm-treatment , Multiple-myeloma-treatment , Bispecifics , Bispecific-antibodies , Relapsed-refractory-multiple-myeloma ,

CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.

Multiple-myeloma , Cell-therapy , Mm , Relapsed-refractory-mm , Rrmm , Mm-treatment , Multiple-myeloma-treatment , Cart-cell-therapy , Targeted-therapy , Bispecifics , Combination-therapy

GPRC5D-Targeting Bispecifics in Multiple Myeloma

The expert panel discusses recent clinical trial data on GPRC5D-targeting bispecific antibodies and how they apply to the multiple myeloma treatment paradigms.

Multiple-myeloma , Targeting-bispecifics , Mm , Relapsed-refractory-mm , Rrmm , Mm-treatment , Multiple-myeloma-treatment , Gprc5d , Gprc5d-bispecific , Targeted-therapy , Talquetamab

Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma

Experts on multiple myeloma discuss how real-world evidence informs treatment selection for patients receiving bispecific antibodies.

Multiple-myeloma , World-evidence , Selecting-optimal-bispecifics , Mm , Relapsed-refractory-mm , Rrmm , Mm-treatment , Bispecifics , Bcma , Teclistamab , Elranatamab

Step-Up Dosing Practices for Bispecifics in Multiple Myeloma

Multiple myeloma specialists compare step-up dosing practices and provide clinical insights on treating patients with multiple myeloma.

Multiple-myeloma , Mm , Relapsed-refractory-mm , Rrmm , Mm-treatment , Inpatient-treatment , Outpatient-treatment , Step-up-dosing , High-tumor-burden , Crs , Safety-considerations

Potential Role for CAR T-Cell Therapy in MM at Early Relapse

Krina Patel, MD, reviews data from the CARTITUDE-4 and KarMMa-3 studies and shares perspectives on a potential role for CAR T-cell therapy at early relapse.

Krina-patel , Multiple-myeloma , Cell-therapy , Mm , Early-relapse , Relapsed-refractory-mm , Rrmm , Mm-treatment , Cart-cell-therapy , Cartitude-2 , Cartitude-4

Treatment of Multiple Myeloma at Early Relapse

A panel of expert hematologic-oncologists offer insights on how they treat patients with multiple myeloma at early relapse.

Multiple-myeloma , Mm , Early-relapse , Relapsed-refractory-mm , Rrmm , Mm-treatment , Daratumumab , Carfilzomib , Pomalidomide , Dexamethasone , Dkd

The Evolving Treatment Paradigm for Transplant Ineligible MM

The expert panel discusses how the standard of care for transplant-ineligible NDMM has evolved and reviews recent updates in this space.

Multiple-myeloma , Evolving-treatment-paradigm , Transplant-ineligible , Mm , Newly-diagnosed-multiple-myeloma , Ndmm , Mm-treatment , Transplant-eligible , Daratumumab , Lenalidomide , Dexamethasone

Evolving Treatment Landscape of Relapsed/Refractory Multiple Myeloma

Rafat Abonour, MD briefly summarizes the current treatment landscape for Relapsed/Refractory Multiple Myeloma (R/R MM) and discusses the diverse strategies and advancements in managing this complex disease.

Rafat-abonour , Refractory-multiple-myeloma , Treatment-landscape , Refractory-multiple , Relapsed-refractory-multiple-myeloma , Relapsed-refractory-mm , Multiple-myeloma , Mm-treatment , Multiple-myeloma-treatment , Ash-2023 , Rr-mm

Highlights from ASH 2023 in Transplant-Eligible NDMM

Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.

Multiple-myeloma , Mm , Newly-diagnosed-multiple-myeloma , Ndmm , Mm-treatment , Transplant-eligible , Perseus , Griffin-trial , Perseus-trial , Daratumumab , Lenalidomide